US Patent

US12569474 — Compositions and methods for treating anemia

Method of Use · Assigned to Akebia Therapeutics Inc · Expires 2034-06-04 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects specific doses and dosing regimens for using a HIF prolyl hydroxylase inhibitor, such as vadadustat, to treat or prevent anemia.

USPTO Abstract

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Drugs covered by this patent

vadadustat (VADADUSTAT)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3876`	—	vadadustat
`U-3876`	—	vadadustat
`U-3876`	—	vadadustat

Patent Metadata

Patent number: US12569474
Jurisdiction: US
Classification: Method of Use
Expires: 2034-06-04
Drug substance claim: No
Drug product claim: No
Assignee: Akebia Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.